BioSpace News Archive

Rakuten Medical has appointed two new directors to the company’s Board: David Chao, co-founder and General Partner of DCM Ventures; and Kentaro Hyakuno, Chief Operating Officer and Group Executive Vice President of Rakuten, Inc.

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $84.9 million.

Demonstrates strong safety and oral PK

Management will present an overview of Charles River’s strategic focus and business developments.

A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com.

An audio webcast of the Stifel presentation will be available online at OrthoPediatrics’ investor relations website, http://ir.orthopediatrics.com. Additionally, a replay will be available for 90 days after the presentation.

DNAtrix’s oncolytic virus technology will be highlighted across six additional abstracts selected for presentation.

The webcast will be recorded and available for replay on the Company’s website for 14 days.

Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic steatohepatitis (NASH) and liver fibrosis

Lev El Diagnostics of Heart Diseases Ltd. (Lev-El), announced the results of the world’s largest prospective multi-center clinical study to evaluate the correlation between heart rate variability (HRV) and the presence of myocardial ischemia in healthy individuals without known coronary artery disease (CAD) that will be presented at The American Heart Association’s (AHA) 2019 Annual Scientific Sessions